Based on prior preclinical studies targeting RAS pathway signaling molecules (MEK,5 mTOR21), mirdametinib and everolimus, respectively, have entered clinical trials for children with low-grade glioma, including those with NF1-OPG [NCT01158651; NCT04923126].16 This evidence concerns the gene NF1 and glioma.